Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Ramelteon Modified-Release vs Rozerem in Healthy Chinese Subjects
NCT06890715Phase 1Completed
- Sponsor
- Overseas Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ramelteon in Insomnia (2 arms), sponsored by Overseas Pharmaceuticals. Primary endpoints: Area under the curve from time zero to the time of the last quantifiable plasma concentration at 1 month, Peak concentration at each treatment period at 1 month and 1 more. Started Jun 2024; status: completed.
02
Drugs
ramelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06890715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890715.